{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:43:41Z","timestamp":1790034221320,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the health and economic impact of the varicella vaccination program on varicella disease in the United States (US), 1996\u20132020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analysis was conducted using the Centers for Disease Control and Prevention or published annual population-based varicella incidence, and varicella-associated hospitalization, outpatient visit, and mortality rates in the US population aged 0\u201349 years during 1996\u20132020 (range, 199.5\u2013214.2 million persons) compared to before vaccination (1990\u20131994). Disease costs were estimated using the societal perspective. Vaccination program costs included costs of vaccine, administration, postvaccination adverse events, and travel and work time lost to obtain vaccination. All costs were adjusted to 2020 US dollars using a 3% annual discount rate. The main outcome measures were the number of varicella-associated cases, hospitalizations, hospitalization days, and premature deaths prevented; life-years saved; and net societal savings from the US varicella vaccination program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among US persons aged 0\u201349 years, during 1996\u20132020, it is estimated that more than 91 million varicella cases, 238 000 hospitalizations, 1.1 million hospitalization days, and almost 2000 deaths were prevented and 118 000 life-years were saved by the varicella vaccination program, at net societal savings of $23.4 billion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Varicella vaccination has resulted in substantial disease prevention and societal savings for the US over 25 years of program implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiac271","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T11:52:10Z","timestamp":1661341930000},"page":"S463-S469","source":"Crossref","is-referenced-by-count":18,"title":["Health and Economic Impact of the United States Varicella Vaccination Program, 1996\u20132020"],"prefix":"10.1093","volume":"226","author":[{"given":"Fangjun","family":"Zhou","sequence":"first","affiliation":[{"name":"Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Marin","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L","family":"Dooling","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara C","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael R","family":"Ortega-Sanchez","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2022102100075639100_jiac271-B1","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56(RR-4)","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"2022102100075639100_jiac271-B2","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac221","article-title":"Monitoring varicella vaccine impact on varicella incidence in the United States: surveillance challenges and changing epidemiology, 1995\u20132019","author":"Marin","year":"2022","journal-title":"J Infect Dis"},{"key":"2022102100075639100_jiac271-B3","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac242","article-title":"Decline in severe varicella disease during the United States varicella vaccination program: hospitalizations and deaths, 1990\u20132019","author":"Marin","year":"2022","journal-title":"J Infect Dis"},{"key":"2022102100075639100_jiac271-B4","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac337","article-title":"Celebrating 25 years of varicella vaccination coverage for children and adolescents in the United States: a success story","author":"Elam-Evans","year":"2022","journal-title":"J Infect Dis"},{"key":"2022102100075639100_jiac271-B5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jama.294.7.797","article-title":"Impact of varicella vaccination on health care utilization","volume":"294","author":"Zhou","year":"2005","journal-title":"JAMA"},{"issue":"Suppl 2","key":"2022102100075639100_jiac271-B6","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1086\/522135","article-title":"An economic analysis of the universal varicella vaccination program in the United States","volume":"197","author":"Zhou","year":"2008","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2022102100075639100_jiac271-B7","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1002\/jmv.10364","article-title":"Varicella in Americans from NHANES III: implications for control through routine immunization","volume":"70","author":"Kilgore","year":"2003","journal-title":"J Med Virol"},{"key":"2022102100075639100_jiac271-B8","doi-asserted-by":"crossref","first-page":"ofv006","DOI":"10.1093\/ofid\/ofv006","article-title":"Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009\u20132010","volume":"2","author":"Lebo","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2022102100075639100_jiac271-B9","year":"2021"},{"key":"2022102100075639100_jiac271-B10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/003335491412900108","article-title":"Comparing active and passive varicella surveillance in Philadelphia, 2005-2010: recommendations for the transition to nationwide passive varicella disease surveillance","volume":"129","author":"Viner","year":"2014","journal-title":"Public Health Rep"},{"key":"2022102100075639100_jiac271-B11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/jpids\/piv044","article-title":"Impact of the maturing varicella vaccination program on varicella and related outcomes in the United States: 1994-2012","volume":"5","author":"Leung","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2022102100075639100_jiac271-B12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.1994.03510290057037","article-title":"Cost-effectiveness of a routine varicella vaccination program for US children","volume":"271","author":"Lieu","year":"1994","journal-title":"JAMA"},{"key":"2022102100075639100_jiac271-B13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00006454-199403000-00001","article-title":"The cost of childhood chickenpox: parents\u2019 perspective","volume":"13","author":"Lieu","year":"1994","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 2","key":"2022102100075639100_jiac271-B14","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1086\/522138","article-title":"Varicella outbreak reporting, response, management, and national surveillance","volume":"197","author":"Leung","year":"2008","journal-title":"J Infect Dis"},{"key":"2022102100075639100_jiac271-B15","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac214","article-title":"Changing epidemiology of varicella outbreaks in the United States during the varicella vaccination program, 1995\u20132019","volume-title":"J Infect Dis","author":"Leung","year":"2022"},{"key":"2022102100075639100_jiac271-B16","volume-title":"Prevention effectiveness: a guide to decision analysis and economic evaluation","author":"Haddix","year":"2003"},{"key":"2022102100075639100_jiac271-B17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/13696998.2018.1542520","article-title":"Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations","volume":"22","author":"Grosse","year":"2019","journal-title":"J Med Econ"},{"key":"2022102100075639100_jiac271-B18","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0264-410X(01)00433-9","article-title":"Frequency and causes of vaccine wastage","volume":"20","author":"Setia","year":"2002","journal-title":"Vaccine"},{"key":"2022102100075639100_jiac271-B19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1542\/peds.2013-0698","article-title":"Economic evaluation of the routine childhood immunization program in the United States, 2009","volume":"133","author":"Zhou","year":"2014","journal-title":"Pediatrics"},{"key":"2022102100075639100_jiac271-B20","article-title":"Varicella virus vaccine live: a 22-year review of postmarketing safety data","volume":"6:ofz295","author":"Woodward","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 2","key":"2022102100075639100_jiac271-B21","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1086\/522161","article-title":"Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995\u20132005","volume":"197","author":"Chaves","year":"2008","journal-title":"J Infect Dis"},{"key":"2022102100075639100_jiac271-B22","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac306","article-title":"Safety surveillance of varicella vaccines in the vaccine adverse event reporting system, United States, 2006\u20132020","author":"Moro","year":"2022","journal-title":"J Infect Dis"},{"key":"2022102100075639100_jiac271-B23","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"2022102100075639100_jiac271-B24","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac255","article-title":"The impact of universal varicella vaccination on herpes zoster incidence in the United States: comparison of birth cohorts preceding and following varicella vaccination program launch","author":"Leung","year":"2022","journal-title":"J Infect Dis"},{"key":"2022102100075639100_jiac271-B25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/14760584.2019.1646129","article-title":"Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States","volume":"18","author":"Harpaz","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2022102100075639100_jiac271-B26","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"2022102100075639100_jiac271-B27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2917","article-title":"Incidence of herpes zoster among children: 2003-2014","volume":"144","author":"Weinmann","year":"2019","journal-title":"Pediatrics"},{"key":"2022102100075639100_jiac271-B28","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1016\/j.vaccine.2020.05.006","article-title":"Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine","volume":"38","author":"Weinmann","year":"2020","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_4\/S463\/46582574\/jiac271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_4\/S463\/46582574\/jiac271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T15:39:26Z","timestamp":1676475566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/Supplement_4\/S463\/6764814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":28,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac271","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,10,21]]}}}